Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Letter

Probiotics: an obedient ally or an insidious enemy?

Metaxia N Papanikolaou*, Margarita Balla, Theonymfi Papavasilopoulou, Georgios Kofinas and Stylianos Karatzas

Author Affiliations

Intensive Care Unit, Hippokrateion General Hospital of Athens, 114, Vas. Sophias Ave., 11521 Athens, Greece

For all author emails, please log on.

Critical Care 2012, 16:456  doi:10.1186/cc11806


The electronic version of this article is the complete one and can be found online at: http://ccforum.com/content/16/6/456


Published:5 November 2012

© 2012 BioMed Central Ltd

Letter

The first case of bloodstream infection by Pediococcus pentosaceus after the administration of a symbiotic formula to a critically ill patient is presented. The infection was successfully treated with ceftriaxone.

Probiotics are increasingly used in the intensive care unit (ICU), mainly for the management of intractable diarrhea. As probiotics are living organisms, one risk following their administration is infection of the host, primarily by Lactobacillus rhamnosus or Saccharomyces boulardii [1]. This is the first report of a bloodstream infection by Pediococcus pentosaceus following symbiotic administration to a critically ill patient.

A 64-year-old man with severe acute gallstone pancreatitis was admitted to our ICU; he had an APACHE II (Acute Physiology and Chronic Health Evaluation II) score of 35 and a Ranson score of 7. He stayed in the ICU for 191 days and eventually died of multiorgan failure. During his stay, he developed recurrent intra-abdominal abscesses for which he required both percutaneous drainage and surgical debridement. He was given total parenteral nutrition because of persistent diarrhea. The stool cultures were negative for Clostridium difficile toxin. As all other measures to control the diarrhea failed, we administered a probiotic-prebiotic combination on day 43. This was a formula with 4 × 1010 bacteria once daily: 1010 colony-forming units of each of P. pentosaceus, Leuconostoc mesenteroides, L. paracasei, and L. plantarum and also 2.5 g of inulin, oat bran, pectin, and resistant starch (Synbiotic 2000 Forte; Medifarm, Kagerod, Sweden). On day 45, the patient became septic and had a temperature of 39°C, a white blood cell count of 14,350/mm3, and a C-reactive protein of 100 mg/dL. Blood cultures revealed the presence of P. pentosaceus (VITEK II; bioMérieux, Marcy l'Etoile, France) susceptible to penicillin G, ampicillin, ceftriaxone, erythromycin, and daptomycin. The probiotic was discontinued, and ceftriaxone was started. The patient responded to treatment and improved gradually. We believe that the bacteremia was triggered by the probiotic formula.

Most probiotics can be safely used in patients receiving nutritional support. The formula that we administered has been extensively used before, and to the best of our knowledge, there were no reports relating this formula to infectious complications [2]. Nonetheless, in a recent clinical trial, an unexpected increase in mortality in probiotic-treated patients with severe pancreatitis was found; this increase cannot be ignored and calls into question the safety of probiotics [3].

Bloodstream infections by probiotics can be attributed to translocation across gut mucosa, to central venous catheter (CVC) contamination, or to massive colonization [4]. In our case, translocation seems the most likely hypothesis; the tip of the CVC was sterile, and cultures from different sites (bronchial secretions, peritoneal fluids, and urine) were all negative. We conclude that P. pentosaceus bacteremia could be an emerging threat in critically ill patients receiving symbiotic formulas, despite their acceptable safety profile.

Abbreviations

CVC: central venous catheter; ICU: intensive care unit.

Competing interests

The authors declare that they have no competing interests.

References

  1. Whelan K, Myers CE: Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized control trials, and nonrandomized trials.

    Am J Clin Nutr 2010, 91:687-703. PubMed Abstract | Publisher Full Text OpenURL

  2. Kotzampassi K, Giamarellos-Bourboulis E, Voudouris A, Kazamias P, Eleftheriadis E: Benefits of a symbiotic formula (Synbiotic 2000 forte) in critically ill trauma patients: early results of a randomized controlled study.

    World J Surg 2006, 30:1848-1855. PubMed Abstract | Publisher Full Text OpenURL

  3. Morrow LE, Gogineni V, Malesker MA: Synbiotics and probiotics in the critically ill after the PROPRATRIA trial.

    Curr Opin Clin Nutr Metab Care 2012, 15:147-150. PubMed Abstract | Publisher Full Text OpenURL

  4. Lolis N, Veldekis D, Moraitou H, Kanavaki S, Velegraki A, Triandafyllidis C, Tasioudis C, Pefanis A, Pneumaticos I: Saccharomyces boulardii fungemia in an intensive care unit patient treated with caspofungin.

    Crit Care 2008, 12:414. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL